Helix Biopharma Corp is Shariah compliant. The company’s financials pass three standards and fail in two.
Ad
HBP – Helix Biopharma Corp
Compliant
★★★☆☆
- Biotechnology & Medical Research
- Toronto Stock Exchange
- July 16, 2022
$24,674,807
Market cap
-
Revenue Growth
-
Analysts' Rating
AAOIFI
S&P
DJIM
FTSE
MSCI
AAOIFI
AAOIFI ✓
| Debt ÷ Market cap (MC) | 11.74% | ✓ |
| Non-Compliant Assets ÷ MC | % |
S&P
S&P ✓
| Debt ÷ 36 mo MC | 3.88% | ✓ |
| Cash ÷ 36 mo MC | 3.83% | ✓ |
| AR ÷ 36 mo MC | % |
DJIM
DJIM ✓
| Debt ÷ 24 mo MC | 4.58% | ✓ |
| Cash ÷ 24 mo MC | 4.52% | ✓ |
| AR ÷ 24 mo MC | % |
FTSE
FTSE ✗
| Debt ÷ Assets | 88.86% | ✗ |
| Cash ÷ Assets | 87.7% | ✗ |
| Cash&AR ÷ Assets | 87.7% | ✗ |
MSCI
MSCI ✗
| Debt ÷ Assets | 88.86% | ✗ |
| Cash ÷ Assets | 87.7% | ✗ |
| Cash&AR ÷ Assets | 87.7% | ✗ |
Ad
N/A
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Total Analysts: 0
Company Profile
Helix BioPharma Corp. (Helix) is an immuno-oncology company that is developing drug candidates for the prevention and treatment of cancer. Helix’s proprietary technological platforms include DOS47, V-DOS47 and L-DOS47. The DOS47 is an oncology platform that offers a debilitation and destruction of cancer cells by modulating the tumor microenvironment. DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2) and can be used in several types of solid tumors.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Ad
Responses